---
title: MYR (Exit)
date: 2014-10-13T08:26:19Z
modified: 2026-08-11T11:17:02Z
permalink: "https://www.htgf.de/en/portfolio/htgffamily/myr-2/"
type: portfolio
status: publish
excerpt: ""
wpid: 2028
language:
  - English
post_translations:
  - pll_5449264da2472
branchen22:
  - Pharmaceuticals
sectors:
  - Pharmaceuticals
focus_areas:
  - Other
timestamp: 2026-08-11T11:17:02Z
tags:
  - English
  - pll_5449264da2472
  - Pharmaceuticals
  - Other
---

## Beschreibungstext

First-in-class Entry-Inhibitor for the treatment of chronic hepatitis Delta

## Lange Beschreibung

MYR, acquired by Gilead Sciences in 2021, developed a peptide-based, first-in-class drug to combat chronic hepatitis delta. The drug has been approved by the EMA for the treatment of chronic hepatitis delta in Europe and is in preparation for approval by the US FDA.

## Adresse

Eiermarkt 3c
30938 Burgwedel

## Kontakt

Array

Array